Progress novel assets (one FIH start) for non-tubercular mycobacteria that may act synergistically with bedaquiline and cytochrome bc drugs


Start Date
End Date
IMI2 - Call 16
Grant agreement number

Type of Action: 
RIA (Research and Innovation Action)

IMI Funding
5 687 984
EFPIA in kind
2 357 657
15 000
Total Cost
8 060 641


Non-tuberculous mycobacteria (NTM) cause lung diseases that look like (but are not) tuberculosis (TB), mainly in people with weakened immune systems or patients with other lung diseases such as cystic fibrosis. NTM infections are caused by bacteria such as Mycobacterium avium complex and Mycobacterium abscessus, both of which are related to the TB-causing bacteria Mycobacterium tuberculosis. Cases of NTM disease are on the rise worldwide, and in regions where TB is largely under control, NTM is much more common than TB. Although treatments exist for the most common NTM infections, they do not always work well, and the complex treatment regimen can last as long as two years. Studies have shown that there are now cases of multi-drug resistant NTM. The goal of RespiriNTM is to find new drug candidates that could be part of a new, more efficient drug regimen for NTM with a shorter treatment time. The team will focus its efforts on the respiratory pathway of the bacteria that cause the disease. They will also carry out research to identify new drug targets that could be used to attack NTM bacteria. Finally, the team will study the factors that allow NTM bacteria to survive in humans.

RespiriNTM is part of the IMI AMR Accelerator Programme.

Participants Show participants on map

EFPIA companies
  • Janssen Pharmaceutica Nv, Beerse, Belgium
Universities, research organisations, public bodies, non-profit groups
  • Academisch Ziekenhuis Leiden, Leiden, Netherlands
  • Kobenhavns Universitet, Copenhagen, Denmark
  • Medizinische Universitaet Wien, Vienna, Austria
  • Sorbonne Universite, Paris, France
  • Universiteit Antwerpen, Antwerp, Belgium
  • Universiteit Leiden, Leiden, Netherlands
Small and medium-sized enterprises (SMEs) and mid-sized companies (<€500 m turnover)
  • Ffund BV, Amsterdam, Netherlands
  • Mitologics, Romainville, France
Project coordinator
Meindert H. Lamers
Academisch Ziekenhuis Leiden